Press Releases

The global emerging infectious disease diagnostics market was USD 20.20 billion in 2023 and is expected to reach USD 32.50 billion by 2030 with a CAGR of 6.44% during the forecast period, i.e., 2025-2030. Emerging infectious disease diagnostics involves the identification and monitoring of novel pathogens that pose a threat to public health. It encompasses a suite of diagnostic tools and technologies designed to rapidly and accurately detect emerging infectious agents, facilitating prompt response and containment measures. Ongoing innovations in diagnostic technologies, such as PCR, next-generation sequencing, and immunodiagnostics, enhance the precision and speed of pathogen detection coupled with the Increasing global collaboration, surveillance systems, and proactive preparedness efforts contribute to early detection, swift response, and a growing demand for effective diagnostic solutions; however, the global emerging infectious disease diagnostics market is facing challenges such as stringent and varying regulatory processes across regions, limited access to advanced diagnostics in resource-limited settings, and rapidly evolving pathogens and unpredictable characteristics of emerging diseases, which makes it challenging to develop diagnostics in advance, necessitating adaptable solutions for effective response.

In June 2023, Delve Bio, backed by a $35 million Series A funding led by PXV Fund II, Section 32, and GV, is set to commercialize its metagenomic next-generation sequencing (mNGS) infectious disease test. Developed at UCSF, the test departs from conventional approaches by simultaneously detecting bacteria, fungi, parasites, and viruses in a single patient sample, expediting accurate pathogen identification. Delve aims to address diagnostic limitations, reduce unnecessary testing, and enhance precision in infectious disease diagnostics, reflecting a paradigm shift from traditional methods. The funding will also support the development of additional next-generation tests in their pipeline.

Browse 75 market data Tables and 45 Figures spread through 226 Pages and in-depth TOC on "Global Emerging Infectious Disease Diagnostics Market, by Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, and Other Technologies), by Type of Infection (Viral, Bacterial, Fungal, and Others), by Disease Type (Respiratory Infections, Sexually Transmitted Infections (STIs), Gastrointestinal Infections, and Other Infections), By Application (Laboratory Testing and Point-of-Care Testing), by End-User (Hospitals and Clinics, Diagnostics Laboratories, and Other End-User), and by Region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Global Forecast to 2030

Global Emerging Infectious Disease Diagnostics Market Segmentation and Key Players

By technology, degradable emerging infectious disease diagnostics dominate the global emerging infectious disease diagnostics market.

Based on technology, the global emerging infectious disease diagnostics market is segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), immunodiagnostics, and other technologies. Polymerase Chain Reaction (PCR) dominated the global emerging infectious disease diagnostics market in 2023 due to its precision and speed. PCR's crucial role was evident in the rapid and accurate detection of pathogens, particularly during the ongoing COVID-19 pandemic. Examples include the widespread use of PCR tests, like Roche's cobas SARS-CoV-2 Test, offering high sensitivity and specificity. The established track record, versatility, and reliability of PCR technology positioned it as a frontline tool, underscoring its dominance in diagnosing and managing emerging infectious diseases.

“The Asia-Pacific (APAC) is expected to register the fastest CAGR during the forecast period in the global emerging infectious disease diagnostics market.”

The Asia-Pacific is expected to registered the highest CAGR the global emerging infectious disease diagnostics market owing to due to due to the region's rising healthcare infrastructure, increasing awareness, and large population density. The demand for effective diagnostics is underscored by recent outbreaks like the COVID-19 outbreak in China and the Nipah virus in India. Investments in healthcare systems, coupled with the urgency to address infectious diseases, position the Asia-Pacific region as a key growth driver. Governments and organizations are likely to prioritize advancements in diagnostic technologies, contributing to the region's significant growth in the emerging infectious disease diagnostics market.

Some of the major players in the global emerging infectious disease diagnostics market include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc., Co-Diagnostics, Inc., DANAHER CORPORATION, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Hologic, Inc., QIAGEN N.V., QuidelOrtho Corporation, T2 Biosystems, Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Siemens Healthineers AG.

Global Emerging Infectious Disease Diagnostics Market Coverage (By Value)

• By Technology Insight and Forecast 2025-2030

• Polymerase Chain Reaction (PCR)

• Isothermal Nucleic Acid Amplification Technology (INAAT)

• Next-Generation Sequencing (NGS)

• Immunodiagnostics

• Other Technologies

• By Type of Infection Insight and Forecast 2025-2030

• Viral

• Bacterial

• Fungal

• Others

• By Disease Type Insight and Forecast 2025-2030

• Respiratory Infections

• Sexually Transmitted Infections (STIs)

• Gastrointestinal Infections

• Other Infections

• By Application

• Laboratory Testing

• Point-of-Care Testing

• End-User Insight and Forecast 2025-2030

• Hospitals and Clinics

• Diagnostics Laboratories

• Other End-User

Geographical Segmentation

Global Emerging Infectious Disease Diagnostics Market by Region

• North America

• By Technology

• By Type of Infection

• By Disease Type

• By Application

• By End-user

• By Country – U.S., Canada, and Mexico

• Europe

• By Technology

• By Type of Infection

• By Disease Type

• By Application

• By End-user

• By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe

• Asia-Pacific (APAC)

• By Technology

• By Type of Infection

• By Disease Type

• By Application

• By End-user

• By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific

• South America

• By Technology

• By Type of Infection

• By Disease Type

• By Application

• By End-user

• By Country – Argentina, Brazil, Chile, and Rest of South America

• Middle East and Africa

• By Technology

• By Type of Infection

• By Disease Type

• By Application

• By End-user

• By Country – Saudi Arabia, U.A.E, South Africa, and Rest of Middle East and Africa